5 Biotech Stocks with Biggest Upside

3. Denali Therapeutics Inc. (NASDAQ:DNLI)

Average Target Price: $55.58

Potential Upside: 133.1%

Number of Hedge Fund Holders: 25

Value of Hedge Fund Holdings: $243,606,110

Denali Therapeutics Inc. (NASDAQ:DNLI) is a San Francisco, California-based clinical-stage biotechnology company. It went public in 2018 and is focused on developing therapies for neurodegenerative diseases.

The lead candidates of Denali Therapeutics Inc. (NASDAQ:DNLI) are small molecule inhibitors of LRRK2 kinase for Parkinson’s disease and antibodies targeting TREM2 for Alzheimer’s disease. Other pipeline programs target ALS, dementia with Lewy bodies, and multiple system atrophy, among others. With such a strong pipeline, analysts are bullish on Denali Therapeutics Inc. (NASDAQ:DNLI) as one of the best biotech stocks.